Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A et al
The patient is the only one with direct access to the member portal that shows plan-specific exclusions
Conclusions Although studies have demonstrated the efficacy of GLP-1 receptor agonists (GLP-1 RAs) and SGLT-2 inhibitors in improving conditions associated with new-onset diabetes mellitus (DM) and chronic kidney disease (CKD), there is a scarcity of data regarding their use after liver transplantation
The TRIUMPH clinical trial program includes five doses of retatrutide: 2 mg, 4 mg, 6 mg, 9 mg and 12 mg
However, recent research indicates a concerning trend: approximately 50% of individuals prescribed these second-line therapies discontinue their usage within a year